Machine learning models predict macrophage activation syndrome risk in 737 patients with Still's disease.
This multicenter, prospective observational study enrolled 737 patients with Still's disease within the GIRRCS AOSD Study Group and the AIDA Network Still's Disease Registry. The primary objective was to evaluate the occurrence of macrophage activation syndrome (MAS) and poor prognosis using machine learning techniques, including random forest imputation, regression models, and decision trees. The study population consisted of patients with Still's disease, with MAS occurrence and poor prognosis serving as the primary outcomes of interest.
The analysis revealed that 11.4% of the 737 patients were affected by MAS. Additionally, 3% of patients experienced a poor prognosis. Machine learning models identified a specific combination of features—age ≥ 45 years, ferritin ≥ 4,178.10 ng/mL, CRP ≥ 27.15 mg/L, and a systemic score ≥ 7—which was associated with a 34.7% probability of MAS. A similar probability of 33.5% was observed when age was not included in the model.
Safety and tolerability data, including adverse events, discontinuations, and serious adverse events, were not reported in this study. The authors note that while the combination of identified features may suggest a clinician-friendly algorithm for stratifying MAS probability, the observational design precludes definitive causal conclusions. Key limitations regarding generalizability or external validation were not explicitly detailed in the provided data.
The practice relevance of this study lies in its potential to offer a data-driven approach for risk stratification. However, clinicians must interpret these probability estimates with caution, recognizing that the evidence is derived from an observational registry without a control group or randomized intervention. These results should not be used to replace established clinical judgment or diagnostic criteria.